Showing 2261-2270 of 5964 results for "".
- Fall Clinical PAs & NP Update: Castle's DecisionDx-SCC Can Identify Tumors Likely to Spread in Low-Risk CSCChttps://practicaldermatology.com/news/fall-clinical-pas-np-update/2461778/Castle Biosciences, Inc.’s DecisionDx-SCC test can identify tumors likely to metastasize in patients with cutaneous squamous cell carcinoma deemed low risk by traditional staging, according to research presented at the the 2023 Fall Clinical Dermatology Conference for PAs &am
- Does IL-17 Play a Role in Skin Aging?https://practicaldermatology.com/news/does-il-17-play-a-role-in-skin-aging/2461770/Interleukin (IL)-17 may plays a central role in skin aging, according to research from Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG). The study, which was led by Dr. Guiomar Solanas, Dr. Salvador Azn
- News You Can Use: SID Announces New Research Grant Program Focusing on Type 2 Inflammationhttps://practicaldermatology.com/news/news-you-can-use-sid-announces-new-research-grant-program-focusing-on-type-2-inflammation/2461767/The Society for Investigative Dermatology’s (SID) new research grant program, The SID Type 2 Inflammation Innovation Awards, is open now and the deadline is August 31, 2023
- FDA Clears DeepX Diagnostics Inc.'s DermoSight for Telederm Screening of Suspicious Lesionshttps://practicaldermatology.com/news/fda-clears-deepx-diagnostics-incs-dermosight-for-telederm-screening-of-suspicious-lesions/2461763/The US Food and Drug Administration (FDA) has cleared DeepX Diagnostics Inc.’s digital dermatoscope DermoSight for teledermatology screening of suspected skin cancer lesions. DermoSight is currently cle
- TWi Biotechnology, Yale University Seek Participants With GA for Phase 1 trial of a Topical JAK Inhibitorhttps://practicaldermatology.com/news/twi-biotechnology-yale-university-seek-participants-with-ga-for-phase-1-trial-of-a-topical-jak-inhibitor/2461757/TWi Biotechnology (TWiB) is seeking participants for a Phase 1 clinical trial of a topical gel form of tofacitinib for the treatment of granuloma annulare (GA). Individuals with GA or friends and family members can find study information at:
- Scientists Identify Genomic Cause and Potential Treatment for Disabling Pansclerotic Morpheahttps://practicaldermatology.com/news/scientists-identify-genomic-cause-and-potential-treatment-for-disabling-pansclerotic-morphea/2461756/Researchers have identified genomic variants that cause disabling pansclerotic morphea and have found a potential treatment. People with the disorder have an overactive version of a protein called STAT4, which regulates inflammation and wound healing. The work also identified a drug tha
- EULAR News: Tremyfa Data Shows Sustained Improvements in PsAhttps://practicaldermatology.com/news/eular-news-tremyfa-data-showing-sustained-improvements-in-psa/2461755/Tremfya (guselkumab) provides sustainable improvements in all minimal disease activity (MDA) domains through week 48 in adults with active psoriatic arthritis (PsA) who previously had an inadequate response to one to two tumor necrosis factor inhibitors (TNFi-IR), according to new data
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- EULAR News: Amgen's Otzela Cools Inflammation, May Improve CV Health in PsAhttps://practicaldermatology.com/news/eular-news-amgens-otzela-cools-inflammation-may-improve-cv-health-in-psa/2461749/Otezla (apremilast) showed promising results in cooling inflammation and reducing cardiometabolic risk factors in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), in Milan, Italy. The MOSAIC Phase
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th